CNJ.TO  Cangene Cp




Life Sciences


Market Cap.


Vuru Grade


Current Price

0.00 (0.00%)

Growth Price

Undervalued by 25.65%

Stability Price

Overvalued by 39.67%

Company Metrics

  • P/E 169
  • P/S 2.08
  • P/B 1.25
  • EPS -0.15
  • Cash ROIC 5.13%
  • Cash Ratio 1.47
  • Dividend 0 / 0%
  • Avg. Vol. 255,197.00
  • Shares 66.75M
  • Market Cap. 240.3M

Company Description

Cangene Corporation develops, manufactures, and commercializes therapeutics for infectious diseases or biodefence applications in the United States, Canada, and internationally. The company develops hyperimmunes, which are concentrated specialty antibody preparations made from plasma; and recombinant biopharmaceuticals that are therapeutic proteins made by introducing a particular gene into a host... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Emergent BioSolutions Completes Acquisition of Cangene Corporation
Business Wire (press release) - Feb 21, 2014
ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed its acquisition of Cangene Corporation for $222 million in cash. After payment by Cangene of transaction related costs, Emergent expects ...
Cangene Announces Completion of Acquisition by Emergent BioSolutions - Canada NewsWire (press release)
Emergent BioSolutions pays $222M to acquire life sciences firm Cangene Corp.
Washington Post - Dec 12, 2013
The company took another step toward that goal Tuesday when it agreed to buy Winnipeg, Manitoba-based life sciences company Cangene for $222 million, or $3.24 per share. The combined firm would count roughly 1,400 employees. The acquisition is ...
Emergent BioSolutions strikes $222M deal to buy Cangene Corp. - Baltimore Sun
Cangene bought by US rival for $236-million, latest Canadian biotech taken private - The Globe and Mail
PR Newswire (press release) - May 2, 2011
BALTIMORE AND WINNIPEG, May 2 /PRNewswire/ - Cangene Corporation's Baltimore-based injectable pharmaceutical contract-manufacturing subsidiary, Cangene bioPharma, Inc., has completed a US$11-million renovation of its sterile filling and support ...
Cangene To Be Acquired By Emergent BioSolutions For US$222 Million
Canada NewsWire (press release) - Dec 11, 2013
11, 2013 /CNW/ - Cangene Corporation ("Cangene") (TSX: CNJ) today announced the signing of a definitive agreement under which Emergent BioSolutions ("Emergent") (NYSE: EBS) of Rockville, Maryland will acquire Cangene in an all-cash transaction ...
Cangene takeover might not be a bad thing
Winnipeg Free Press - Dec 20, 2013
The recently announced proposed sale of Cangene Corp. to Emergent BioSolutions Inc. of Maryland for $222 million is bringing up those concerns once again.
Ipsen and Inspiration Biopharmaceuticals Announce Closing of the IB1001 Sale ...
Business Wire (press release) - Feb 20, 2013
Ipsen (Paris:IPN) (Euronext: IPN; ADR: IPSEY) and Inspiration Biopharmaceuticals Inc. (Inspiration) today announced the closing of the sale of the proprietary hemophilia B product, IB1001 (recombinant FIX), to Cangene Corporation (TSX: CNJ) (Cangene).
Ipsen, Inspiration Biopharmaceuticals sell IB1001 hemophilia B product to Cangene -
Cangene Inks $300+M Deal for Bankrupt Inspiration's IB1001 - Genetic Engineering News
Emergent Biosolutions, Inc. Short Interest Update
Insider Trading Report - 8 hours ago
... as the United States Department of Defense (DoD). In August 2013, Emergent Biosolutions Inc closed on its acquisition of Bracco Diagnostics Inc.s Healthcare Protective Products Division.
Updated Recommendations for Use of VariZIG
Medscape - Jul 18, 2013
In December 2012, the Food and Drug Administration (FDA) approved VariZIG, a varicella zoster immune globulin preparation (Cangene Corporation, Winnipeg, Canada) for use in the United States for postexposure prophylaxis of varicella for persons at high ...
Company Shares of Emergent Biosolutions, Inc. (NYSE:EBS) Rally 2.24%
Insider Trading Report - Nov 23, 2015
... as the United States Department of Defense (DoD). In August 2013, Emergent Biosolutions Inc closed on its acquisition of Bracco Diagnostics Inc.s Healthcare Protective Products Division.
Emergent Biosolutions Inc. (EBS) Discloses Form 4 Insider Selling : Exec. Fuad ... - American Trade Journal
Botulism Antitoxin Gets Thumbs-Up from FDA Advisors
Food Safety News - Feb 19, 2013
The drug, developed by Cangene Corporation of Fort Garry, Winnipeg, works to prevent internalization of the toxin in the nerves.